Indivior Pharmaceuticals, Inc. INDV
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a CNS/neurology/psychiatry drug developer. Its lead program, SUBLOCADE (buprenorphine extended-release monthly injection), is marketed for Opioid use disorder.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SUBLOCADE (buprenorphine extended-release monthly injection) | Opioid use disorder | small molecule | Approved |
| SUBOXONE Film (buprenorphine and naloxone sublingual film) | Opioid use disorder | small molecule | Approved |
Recent results and decisions
- Oct 15, 2026n/a Indivior stockholders approved the issuance of shares in connection with a merger at a special meeting.
To approve the issuance of the Indivior Shares in connection with the Merger as contemplated by the Merger Agreement, including for purposes of complying with the applicable provisions of Nasdaq Rule 5635
Filing - Apr 30, 2026missed Phase 2 proof-of-concept study of INDV-2000 in OUD did not meet its primary endpoint of no treatment failure; Indivior will not advance it internally.
INDV-2000 did not meet the primary endpoint of “no treatment failure.”
Filing - Apr 30, 2026discontinued Indivior will not pursue Phase 3 development of INDV-6001 and amended its license with Alar, which regains development rights.
Indivior does not intend to pursue Phase 3 development of INDV-6001 and has amended its license agreement with Alar Pharmaceuticals.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.